Construction and immunogenicity of recombinant swinepox virus expressing capsid protein of PCV2

摘要: To explore development of a vaccine against PCV2 infections, the gene capsid protein (Cap) was inserted into swinepox virus (SPV) genome by homologous recombination. The recombinant expressing (rSPV-cap) verified PCR, western blot and immunofluorescence assays. evaluate immunogenicity rSPV-cap, twenty-four seronegative minipigs were immunized with wild type SPV (wtSPV; negative control), or PBS (challenge control). After inoculation PCV2, pigs in rSPV-cap group showed significantly higher average daily weight gain (ADG) shorter fever duration compared wtSPV treated (P < 0.05). Cap-specific antibody increased dramatically after vaccination continuously over time. genomic copies serum less at all time points 0.01). Significant reduction gross lung lesion scores, histopathological lymph node scores noted results suggested that provided significant protection from PCV2-associated disease; thus, it offers proof-of-principle for prevention disease pigs.